Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06246799 · ClinicalTrials.gov registry record · Phase 3
Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes
A Phase 3 study of Type 2 Diabetes (Adult Onset), sponsored by The University of Texas Health Science Center at San Antonio.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 256
- Enrollment target
- 2
- Study locations
NCT06246799: Recruiting Phase 3 study of Type 2 Diabetes (Adult Onset), sponsored by The University of Texas Health Science Center at San Antonio.
NCT06246799 is a Phase 3 study of Type 2 Diabetes (Adult Onset) that is actively recruiting participants, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 256 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (67% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06246799, a Phase 3 study of Type 2 Diabetes (Adult Onset), is actively recruiting participants, sponsored by The University of Texas Health Science Center at San Antonio.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 256 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary purpose of this study is to evaluate the efficacy, durability, and mechanism of HbA1c reduction produced by the combination of pioglitazone plus tirzepatide compared to metformin plus sitagliptin in patients with recently diagnosed type 2 diabetes mellitus.
Primary Outcome
Therapy failure will be determined as HbA1c \>6.5% in two consecutive HbA1c measurements 3 months apart. Time to cumulative incidence of therapy failure curves will be created in subjects receiving pioglitazone/tirzepatide versus subjects receiving metformin/sitagliptin
Conditions Studied
Interventions
- DRUG Tirzepatide
- DRUG Pioglitazone
- DRUG Sitagliptin
- DRUG Metformin HCI XR
Study Locations (2)
Texas
- University Health System Texas Diabetic Institute - San Antonio
- UT Health Science Center - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2024-11-07 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 3 |
What NCT06246799 shows while recruiting
NCT06246799 is an interventional study that assigns participants to a tested intervention. The registered 256 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Type 2 Diabetes (Adult Onset) appearing as the primary indexed condition, and to 4 interventions - of which Tirzepatide is the first listed.
NCT06246799 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06246799 about?
NCT06246799 is a clinical study titled "Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes". The primary purpose of this study is to evaluate the efficacy, durability, and mechanism of HbA1c reduction produced by the combination of pioglitazone plus tirzepatide compared to metformin plus sitagliptin in patients with recently diagnosed type 2 diabetes mellitus.
What is the current status of trial NCT06246799?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 256 participants. The study started on 2024-11-07. Estimated completion is 2029-06-30.
What conditions does trial NCT06246799 study?
This clinical trial studies the following conditions: Type 2 Diabetes (Adult Onset).
What interventions are being tested in trial NCT06246799?
The interventions under investigation include: Tirzepatide (DRUG), Pioglitazone (DRUG), Sitagliptin (DRUG), Metformin HCI XR (DRUG).
Who is sponsoring clinical trial NCT06246799?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06246799 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes (Adult Onset)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06246799's enrollment target sits among peer trials
256 1241st of 2000 higher than 759 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02464696 · 256 participants · NA
Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure
- NCT03793062 · 256 participants
Genetic and Epigenetic Basis of Chronic Wounds
- NCT04322318 · 256 participants · Phase 2
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
- NCT04468360 · 256 participants · Phase 2
Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI